Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.61 |
| ▸ | TLR2 | O60603 | 1/20 | 0.61 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.61 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17894427 | 0.84 | TLR2 (0.46) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL29746159 | 0.84 | ERN1 (0.53) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL15028567 | 0.82 | TLR2 (0.46) | ERN1TLR2TLR1TLR6LMNA | |
| SCHEMBL15012751 | 0.82 | TLR2 (0.46) | ERN1TLR2TLR1TLR6LMNA | |
| SCHEMBL4898660 | 0.82 | ALDH1A1 (0.50) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL23633015 | 0.80 | ALDH1A1 (0.46) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL31362059 | 0.80 | ERN1 (0.61) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL16959417 | 0.80 | ALDH1A1 (0.43) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL2988767 | 0.80 | ERN1 (0.61) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL16951057 | 0.80 | TLR2 (0.47) | ERN1TLR2TLR1TLR6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3997096-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | claimed |
| CN-118488953-A | Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors | 豪夫迈·罗氏有限公司 | 2024-08-13 | — | — | CN | claimed |
| US-20220242876-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-04 | — | — | US | claimed |
| CN-110606855-B | Polysubstituted benzothienoisoquinoline, derivative and synthesis method thereof | 湘潭大学 | 2022-03-18 | — | — | CN | claimed |
| CN-110684997-B | Zinc-plating electroplating liquid and preparation method thereof | 广州三孚新材料科技股份有限公司 | 2021-02-19 | — | — | CN | claimed |
| EP-3737680-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2020-11-18 | — | — | EP | claimed |
| CN-110684997-A | Zinc-plating electroplating liquid and preparation method thereof | 广州三孚新材料科技股份有限公司 | 2020-01-14 | — | — | CN | claimed |
| CN-110606855-A | Polysubstituted benzothienoisoquinoline, derivative and synthesis method thereof | 湘潭大学 | 2019-12-24 | — | — | CN | claimed |
| WO-2019134985-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-07-11 | — | — | WO | claimed |
| CN-104327106-A | Preparation method of high-sterically-hindered arylborate compound | SHENZHEN RES INST THE HONG KONG POLYTECHNIC UNIVERSITY | 2015-02-04 | — | — | CN | claimed |
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12576156-B2 | Compound comprising self-immolative group and ligand-drug conjugate comprising same | TRIOAR, INC. (KR) | 2026-03-17 | — | — | US | disclosed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| CN-1044652-A | Pyrrolidine compound and its pharmaceutical use | EISAI CO LTD (JP) | 1990-08-15 | — | — | CN | disclosed |
| EP-0381235-A2 | Pyrrolidine compound and pharmaceutical use | Eisai Co., Ltd. (JP) | 1990-08-08 | — | — | EP | disclosed |
| EP-0011279-B1 | PROCESS FOR THE PREPARATION OF AROMATICALLY SUBSTITUTED ACETIC ACIDS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1982-05-05 | — | — | EP | disclosed |
| US-4268442-A | REACTING AN AROMATIC ALKEHYDE WITH A TRIHALOMETHANE AND AN ALKANETHIOL IN THE PRESENCE OF A BASE AND AN APROTIC SOLVENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1981-05-19 | — | — | US | disclosed |
| US-4024274-A | Benzylamine derivatives and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242876-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP1A2 | ERN1 2020/4885TLR2 4137/4885TLR1 4181/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | ERN1 607/4885TLR2 3834/4885TLR1 3910/4885 |
| US-12576156-B2 | Compound comprising self-immolative group and ligand-drug conjugate comprising same | SLC7A1, CLTC, MSR1 | ERN1 3479/4885TLR2 1090/4885TLR1 319/4885 |
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | MGLL, LIPA, LIPC | ERN1 1772/4885TLR2 4657/4885TLR1 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.